Skip to main content

Viridian Therapeutics, Inc.

VRDN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001590750

In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Viridian Therapeutics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of VRDN: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders2639+13
Shares6.00M13.6M+7.60M (+126.5%)
Value$109.8M$223.7M+$113.9M (+103.7%)

New holders (16)

Institutions that held Viridian Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to VRDN in Q3 2021
InstitutionSharesValue% of portfolio
Frazier Management LLC1,505,200$24.8M1.98%
Logos Global Management LP1,500,000$24.7M1.78%
Vivo Capital, LLC1,300,000$21.4M0.96%
Franklin Resources Inc600,000$9.87M0.00%
Eversept Partners, LP160,000$2.63M0.21%
Maven Securities LTD140,000$2.30M0.26%
Acuta Capital Partners, LLC135,807$2.23M0.80%
Marshall Wace North America L.P.75,000$1.23M0.01%
Polar Asset Management Partners Inc.59,700$982.0K0.01%
Pura Vida Investments, LLC58,096$956.0K0.07%
Driehaus Capital Management LLC50,000$823.0K0.01%
Schonfeld Strategic Advisors LLC44,000$724.0K0.01%
LMR Partners LLP33,508$551.0K0.01%
Walleye Capital LLC22,501$370.0K0.01%
Walleye Trading LLC7,500$123.0K0.00%
Bank of America Corp173$3.00K0.00%

Sold out (3)

Institutions that held Viridian Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of VRDN in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Wellington Management Group LLP578,560$10.6M
Balyasny Asset Management LLC119,478$2.19M
Bailard, Inc.90,500$1.66M